Published in Theranostics on April 23, 2013
Magnetic Nanoparticles in Cancer Theranostics. Theranostics (2015) 1.20
Targeted iron-oxide nanoparticle for photodynamic therapy and imaging of head and neck cancer. ACS Nano (2014) 0.89
Magnetically responsive smart nanoparticles for cancer treatment with a combination of magnetic hyperthermia and remote-control drug release. Theranostics (2014) 0.87
Preparation of folic acid-conjugated, doxorubicin-loaded, magnetic bovine serum albumin nanospheres and their antitumor effects in vitro and in vivo. Int J Nanomedicine (2014) 0.83
In vivo anticancer evaluation of the hyperthermic efficacy of anti-human epidermal growth factor receptor-targeted PEG-based nanocarrier containing magnetic nanoparticles. Int J Nanomedicine (2014) 0.78
Targeted Nanotheranostics for Future Personalized Medicine: Recent Progress in Cancer Therapy. Theranostics (2016) 0.78
Externally modulated theranostic nanoparticles. Transl Cancer Res (2013) 0.78
Modelling mass and heat transfer in nano-based cancer hyperthermia. R Soc Open Sci (2015) 0.78
Folate/NIR 797-conjugated albumin magnetic nanospheres: synthesis, characterisation, and in vitro and in vivo targeting evaluation. PLoS One (2014) 0.77
Simultaneous hyperthermia-chemotherapy with controlled drug delivery using single-drug nanoparticles. Sci Rep (2016) 0.77
Hyperthermia Using Antibody-Conjugated Magnetic Nanoparticles and Its Enhanced Effect with Cryptotanshinone. Nanomaterials (Basel) (2014) 0.76
Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment. Cancer Treat Rev (2016) 0.76
The Smart Drug Delivery System and Its Clinical Potential. Theranostics (2016) 0.76
Copy number variation analysis by ligation-dependent PCR based on magnetic nanoparticles and chemiluminescence. Theranostics (2015) 0.76
Effects of embolic agents with different particle sizes on interventional treatment of uterine fibroids. Pak J Med Sci (2016) 0.75
Combining hard and soft magnetism into a single core-shell nanoparticle to achieve both hyperthermia and image contrast. Ther Deliv (2015) 0.75
Multifunctional Inorganic Nanoparticles: Recent Progress in Thermal Therapy and Imaging. Nanomaterials (Basel) (2016) 0.75
Gold-Coated Superparamagnetic Nanoparticles for Single Methyl Discrimination in DNA Aptamers. Int J Mol Sci (2015) 0.75
Effective elimination of liver cancer stem-like cells by CD90 antibody targeted thermosensitive magnetoliposomes. Oncotarget (2016) 0.75
Folic acid-targeted iron oxide nanoparticles as contrast agents for magnetic resonance imaging of human ovarian cancer. J Ovarian Res (2016) 0.75
Magnetomotive Optical Coherence Elastography for Magnetic Hyperthermia Dosimetry Based on Dynamic Tissue Biomechanics. IEEE J Sel Top Quantum Electron (2015) 0.75
Remotely Triggered Nano-Theranostics For Cancer Applications. Nanotheranostics (2017) 0.75
Thermoacoustic Imaging and Therapy Guidance based on Ultra-short Pulsed Microwave Pumped Thermoelastic Effect Induced with Superparamagnetic Iron Oxide Nanoparticles. Theranostics (2017) 0.75
Molecular Imaging in Nanotechnology and Theranostics. Mol Imaging Biol (2017) 0.75
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release (2000) 14.89
Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev (2008) 8.23
Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov (2003) 6.66
Exchange-coupled magnetic nanoparticles for efficient heat induction. Nat Nanotechnol (2011) 2.45
Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev (2010) 2.37
Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics (2012) 2.35
Magnetic fluid hyperthermia: focus on superparamagnetic iron oxide nanoparticles. Adv Colloid Interface Sci (2011) 2.13
Theranostic nanoshells: from probe design to imaging and treatment of cancer. Acc Chem Res (2011) 2.10
Theranostics: combining imaging and therapy. Bioconjug Chem (2011) 2.01
The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy. Chem Soc Rev (2012) 1.87
Nanomaterials: applications in cancer imaging and therapy. Adv Mater (2011) 1.78
Cancer theranostics: the rise of targeted magnetic nanoparticles. Trends Biotechnol (2011) 1.60
Water-soluble iron oxide nanocubes with high values of specific absorption rate for cancer cell hyperthermia treatment. ACS Nano (2012) 1.38
Chains of magnetosomes extracted from AMB-1 magnetotactic bacteria for application in alternative magnetic field cancer therapy. ACS Nano (2011) 1.32
Magnetic nanoparticle-based hyperthermia for head & neck cancer in mouse models. Theranostics (2012) 1.27
Improving the magnetic resonance imaging contrast and detection methods with engineered magnetic nanoparticles. Theranostics (2012) 1.24
The treatment of multiple myeloma. N Engl J Med (1994) 1.23
Magnetic Nanoparticles and microNMR for Diagnostic Applications. Theranostics (2012) 1.17
Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood (1997) 1.13
Relaxivity optimization of a PEGylated iron-oxide-based negative magnetic resonance contrast agent for T₂-weighted spin-echo imaging. ACS Nano (2012) 1.05
In vitro measurements of temperature-dependent specific heat of liver tissue. Med Eng Phys (2005) 1.00
High-frequency, magnetic-field-responsive drug release from magnetic nanoparticle/organic hybrid based on hyperthermic effect. ACS Appl Mater Interfaces (2010) 0.99
Magnetic nanoparticle-based theranostics. Theranostics (2012) 0.98
Comparison of Two Ultrasmall Superparamagnetic Iron Oxides on Cytotoxicity and MR Imaging of Tumors. Theranostics (2012) 0.97
Investigation of In Vivo Targeting Kinetics of α(v)β(3)-Specific Superparamagnetic Nanoprobes by Time-Resolved MRI. Theranostics (2011) 0.96
Mechanism of magnetic relaxation switching sensing. ACS Nano (2012) 0.91
Electrosprayed synthesis of red-blood-cell-like particles with dual modality for magnetic resonance and fluorescence imaging. Small (2010) 0.81
Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet (2006) 2.15
Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology (2003) 2.10
Retracted The chromatin-remodeling complex WINAC targets a nuclear receptor to promoters and is impaired in Williams syndrome. Cell (2003) 1.88
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood (2005) 1.85
Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med (2002) 1.84
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood (2004) 1.78
Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer (2007) 1.65
A novel experimental strategy to assess the metabolic effects of selective activation of a G(q)-coupled receptor in hepatocytes in vivo. Endocrinology (2013) 1.62
Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res (2009) 1.59
Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia. Cardiovasc Res (2005) 1.55
Widespread endogenization of genome sequences of non-retroviral RNA viruses into plant genomes. PLoS Pathog (2011) 1.52
Clarithromycin-induced eosinophilic pneumonia. Intern Med (2004) 1.52
Clinical characteristics of bacteremia caused by Helicobacter cinaedi and time required for blood cultures to become positive. J Clin Microbiol (2014) 1.48
Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res (2007) 1.48
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol (2006) 1.42
Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) alpha or beta. Endocrinology (2002) 1.40
Dermatomyositis with peripheral nervous system involvement: activation of vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) in vasculitic lesions. Intern Med (2003) 1.40
Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma. Acta Haematol (2015) 1.38
Encapsulated ultrasound microbubbles: therapeutic application in drug/gene delivery. J Control Release (2006) 1.38
Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res (2003) 1.32
Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals. Circulation (2004) 1.32
Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood (2002) 1.31
The variegated mutants lacking chloroplastic FtsHs are defective in D1 degradation and accumulate reactive oxygen species. Plant Physiol (2009) 1.28
High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. Circulation (2004) 1.27
Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest. J Bone Miner Res (2004) 1.26
Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem (2004) 1.24
A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res (2015) 1.23
Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis. J Biol Chem (2005) 1.20
Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models. Cancer Sci (2008) 1.19
Highly oxidized peroxisomes are selectively degraded via autophagy in Arabidopsis. Plant Cell (2013) 1.18
Bone metabolism and oxidative stress in postmenopausal rats with iron overload. Toxicology (2004) 1.18
Protein quality control in chloroplasts: a current model of D1 protein degradation in the photosystem II repair cycle. J Biochem (2009) 1.18
The balance between protein synthesis and degradation in chloroplasts determines leaf variegation in Arabidopsis yellow variegated mutants. Plant Cell (2007) 1.17
Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab (2005) 1.17
Pin1 down-regulates transforming growth factor-beta (TGF-beta) signaling by inducing degradation of Smad proteins. J Biol Chem (2009) 1.16
Association between obesity and polymorphisms in SEC16B, TMEM18, GNPDA2, BDNF, FAIM2 and MC4R in a Japanese population. J Hum Genet (2009) 1.16
Chloroplast biogenesis: control of plastid development, protein import, division and inheritance. Arabidopsis Book (2008) 1.15
Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice. J Biol Chem (2002) 1.13
Transcriptional induction of FosB/DeltaFosB gene by mechanical stress in osteoblasts. J Biol Chem (2004) 1.12
Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One (2010) 1.11
White leaf sectors in yellow variegated2 are formed by viable cells with undifferentiated plastids. Plant Physiol (2007) 1.11
INSIG2 gene rs7566605 polymorphism is associated with severe obesity in Japanese. J Hum Genet (2008) 1.10
Cooperative D1 degradation in the photosystem II repair mediated by chloroplastic proteases in Arabidopsis. Plant Physiol (2012) 1.10
A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone (2009) 1.09
A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome. J Biol Chem (2004) 1.07
HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunol Immunother (2008) 1.07
Relationship between transmission intensity and incidence of dengue hemorrhagic fever in Thailand. PLoS Negl Trop Dis (2008) 1.06
Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. PLoS One (2011) 1.06
Nucling recruits Apaf-1/pro-caspase-9 complex for the induction of stress-induced apoptosis. J Biol Chem (2004) 1.06
Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT. Bone (2011) 1.06
New insights into the types and function of proteases in plastids. Int Rev Cell Mol Biol (2010) 1.06
Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab (2014) 1.05
Essential role of VIPP1 in chloroplast envelope maintenance in Arabidopsis. Plant Cell (2012) 1.04
Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol (2004) 1.03
The lack of mitochondrial AtFtsH4 protease alters Arabidopsis leaf morphology at the late stage of rosette development under short-day photoperiod. Plant J (2009) 1.02
Arabidopsis ELONGATED MITOCHONDRIA1 is required for localization of DYNAMIN-RELATED PROTEIN3A to mitochondrial fission sites. Plant Cell (2008) 1.02
Augmented TLR9-induced Btk activation in PIR-B-deficient B-1 cells provokes excessive autoantibody production and autoimmunity. J Exp Med (2009) 1.01
Influence of chloroplastic photo-oxidative stress on mitochondrial alternative oxidase capacity and respiratory properties: a case study with Arabidopsis yellow variegated 2. Plant Cell Physiol (2008) 1.01
Functional characterization of key structural genes in rice flavonoid biosynthesis. Planta (2008) 1.00
Reference database of biochemical markers of bone turnover for the Japanese female population. Japanese Population-based Osteoporosis (JPOS) Study. Osteoporos Int (2004) 0.99
High-frequency, magnetic-field-responsive drug release from magnetic nanoparticle/organic hybrid based on hyperthermic effect. ACS Appl Mater Interfaces (2010) 0.99
Imaging of size-dependent uptake and identification of novel pathways in mouse Peyer's patches using fluorescent organosilica particles. Nanomedicine (2011) 0.99
Androgen-androgen receptor system protects against angiotensin II-induced vascular remodeling. Endocrinology (2009) 0.98
Mitochondrial dynamics in plant male gametophyte visualized by fluorescent live imaging. Plant Cell Physiol (2008) 0.98
Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models. Oncol Rep (2006) 0.97
Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ Res (2007) 0.97
Secretory proprotein convertases PACE4 and PC6A are heparin-binding proteins which are localized in the extracellular matrix. Potential role of PACE4 in the activation of proproteins in the extracellular matrix. Biochim Biophys Acta (2003) 0.97
TGF-β-related mechanisms of bone destruction in multiple myeloma. Bone (2010) 0.97
Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem (2002) 0.96
A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment. Cancer Res (2007) 0.96
Polymorphisms in NRXN3, TFAP2B, MSRA, LYPLAL1, FTO and MC4R and their effect on visceral fat area in the Japanese population. J Hum Genet (2010) 0.95
Retracted Ligand-selective potentiation of rat mineralocorticoid receptor activation function 1 by a CBP-containing histone acetyltransferase complex. Mol Cell Biol (2002) 0.95
Activation of the heterotrimeric G protein alpha-subunit GPA1 suppresses the ftsh-mediated inhibition of chloroplast development in Arabidopsis. Plant J (2009) 0.95
A conserved, Mg²+-dependent exonuclease degrades organelle DNA during Arabidopsis pollen development. Plant Cell (2011) 0.95